Implementing a tenofovir-based first-line regimen in rural lesotho: Clinical outcomes and toxicities after two years

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 3, 2011, Pages

  Bygrave, Helen ^a   Ford, Nathan ^a,b   Cutsem, Gilles Van ^a,b   Hilderbrand, Katherine ^a,b   Jouquet, Guillaume ^a   Goemaere, Eric ^a   Vlahakis, Nathalie ^a   Triviño, Laura ^a   Makakole, Lipontso ^c   Kranzer, Katharina ^d  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Scott Hospital   (Lesotho)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

antiretroviral therapy; mortality; regimen substitution; tenofovir; toxicity

Indexed keywords

CREATININE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LESOTHO; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NEPHROTOXICITY; NEUROPATHY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RURAL AREA; TOXICITY; TREATMENT OUTCOME;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LESOTHO; MALE; PHOSPHONIC ACIDS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RURAL POPULATION; TREATMENT OUTCOME;

EID: 79951812401     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182097505     Document Type: Article

References (14)

1. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis. 200115;33:865-872. (Pubitemid 32831844)
2. Ford N, Calmy A. Improving first-line antiretroviral therapy in resourcelimited settings. Current Opin HIV AIDS. 2010;5:38-47.
3. Brinkman K. Stavudine in antiretroviral therapy: is this the end? AIDS. 2009;23:1727-1729.
4. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46: 716-723. (Pubitemid 34157656)
5. Grim SA, Romanelli F. Tenofovir disoproxil fumarate. Ann pharmacother. 2003;37:849-859. (Pubitemid 36618375)
6. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201. (Pubitemid 38917996)
7. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260. (Pubitemid 43113030)
8. Pozniak A. Tenofovir: what have over 1 million years of patient experience taught us? Int J Clin Pract. 2008;62:1285-1293. (Pubitemid 351977619)
9. Anon. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva, Switzerland: World Health Organization; 2009.
10. Cohen R, Lynch S, Bygrave H, et al. Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years. J Int AIDS Soc. 2009;12:23.
11. Davidson I, Beardsell H, Smith B, et al. The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study. Antiviral Res. 2010;86:227-229.
12. Callaghan M, Ford N, Schneider H. A systematic review of task-shifting for HIV treatment and care in Africa. Hum Resour Health. 2010;8:8.
13. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:e438.
14. Hawkins C, Achenbach C, Fryda W, et al. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. Journal of acquired immune deficiency syndromes (1999). 2007;45: 304-310. (Pubitemid 47012377)